Cargando…
Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary
BACKGROUND: Hypercholesterolemia is a lipid disorder characterized by excessively high levels of low-density lipoproteins, which encourages fat accumulation in your arteries, hence escalating the chances of heart attack and stroke. Globally, 39% of individuals experience elevated total cholesterol l...
Autores principales: | Vohra, Laiba Imran, Rizwan, Kashf, Saeed, Emaan, Hamza, Muhammad Syed Ali, Ochani, Sidhant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344845/ https://www.ncbi.nlm.nih.gov/pubmed/37439881 http://dx.doi.org/10.1186/s43044-023-00389-8 |
Ejemplares similares
-
Hepatitis is still a major health concern in Pakistan: short communication
por: Ochani, Sidhant, et al.
Publicado: (2023) -
Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018) -
Increased burden of booster shots for COVID-19 amidst vaccine hesitancy in Pakistan
por: Lal, Priyanka Mohan, et al.
Publicado: (2022) -
The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran
por: Elserafy, Ahmed Shawky, et al.
Publicado: (2022) -
Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia
por: Ebenezer, Oluwakemi, et al.
Publicado: (2023)